Bio-Rad Laboratories Financials - Benzinga

Bio-Rad Laboratories Inc

BIONYSE

Trade with Public

Trade with Public

$377.33

0.920.24%

At close: Sep 18, 5:00 PM EST

$377.33

0.920.24%

Pre-Market: 4:56 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Bio-Rad Laboratories Financials

Bio-Rad Laboratories (BIO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est

Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.

Benzinga Newsdesk

PRO
Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.75 by 49.71 percent. This is a 0.38 percent increase over earnings of $2.61 per share from

Benzinga Newsdesk

PRO
Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est

Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.

Benzinga Newsdesk

PRO
Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of $2.54 per share from

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

PRO
Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est

Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5 percent and an

Benzinga Newsdesk